Financial Performance - Consolidated operating expenses for Q2 2024 were $2,620,858, a decrease of $787,302 or 23.1% compared to $3,408,716 in Q2 2023[107]. - Net loss for Q2 2024 decreased to $2,571,440 from $3,282,179 in Q2 2023, with basic and diluted loss per share improving to ($0.34) from ($1.35)[111]. - A significant decrease in general and administrative expenses of $556,309 was attributed to reduced supply costs and other operational efficiencies[107]. - For the three months ended June 30, 2024, expenses decreased by approximately $787,000 compared to the same period in 2023, with cash used in operating and investing activities decreasing by approximately $964,000[114]. - Net cash used in operating activities was approximately $1,748,000 for the three months ended June 30, 2024, a decrease of $734,000 from $2,482,000 in the same period in 2023[129]. - The company anticipates continuing to incur increasing negative cash flows and net losses for the foreseeable future, necessitating additional capital raises[132]. Liquidity and Capital Raising - Cash balance as of June 30, 2024, was $9,072,379, up from $5,441,978 at March 31, 2024, indicating improved liquidity[112]. - The company closed a public offering on May 17, 2024, raising approximately $4.7 million in gross proceeds, with net proceeds around $3.5 million after expenses[113]. - As of June 30, 2024, the company raised $5,379,229 net through equity offerings and warrant exercises, alleviating substantial doubt about its ability to continue as a going concern[114]. - The company raised approximately $5,384,000 from financing activities during the three months ended June 30, 2024, primarily from the sale and issuance of common stock and warrants[130]. - The gross proceeds from the May 2024 public offering were approximately $4.7 million, with net proceeds of approximately $3.5 million after deducting fees and expenses[125]. - As of June 30, 2024, $5,302,617 of 2022 ATM Shares remained available for sale under the 2022 ATM Agreement[118]. - The Class A and Class B warrants from the May 2024 offering have an exercise price of $0.58 per share and are immediately exercisable[123]. Clinical Development - The Hemopurifier has received FDA designation as a "Breakthrough Device" for treating advanced cancer and life-threatening viral infections[90]. - Clinical trials for the Hemopurifier are planned in Australia and India, with ethics approvals obtained for trials involving solid tumors[93][101]. - The company is investigating the use of the Hemopurifier in organ transplant settings to reduce complications from viral infections[103]. - The company is working with NAMSA to manage clinical trials for the Hemopurifier in oncology indications in the U.S. and Australia[92]. - The Hemopurifier has shown potential in capturing various viruses in vitro, including HIV, Ebola, and Zika virus, indicating broad therapeutic applications[96]. - The company expects clinical trial expenses for planned oncology trials in Australia and India to increase for the foreseeable future[131]. Legal and Compliance Risks - The company has identified a material weakness in internal control over financial reporting and is actively implementing measures to remediate it[140]. - The company is not currently involved in any pending or threatened legal proceedings[143]. - Claims made against the company in the ordinary course of business may lead to litigation[143]. - Unfavorable outcomes from litigation could result in monetary damages, fines, or penalties[143]. - The occurrence of adverse outcomes could materially affect the company's operational results[143]. - The company acknowledges the inherent uncertainties associated with litigation[143]. - Potential injunctions could prohibit the company from selling certain products or engaging in specific activities[143]. - The impact of legal proceedings may affect future periods' results of operations[143]. - The company is monitoring claims and litigation risks as part of its business strategy[143]. - Legal proceedings are considered a normal risk in the company's business operations[143]. - The company remains vigilant in managing potential legal challenges[143].

Financial Performance - Aethlon Medical reported a cash balance of approximately $9.1 million as of June 30, 2024[8]. - Consolidated operating expenses for the fiscal first quarter were approximately $2.6 million, a decrease of approximately $800,000 or 24% compared to $3.4 million in the same period of 2023[8]. - The decrease in operating expenses was primarily due to a $600,000 reduction in general and administrative expenses and a $300,000 reduction in professional fees[8]. - The net loss for the fiscal quarter ended June 30, 2024, decreased to approximately $2.6 million from approximately $3.3 million in the same quarter of 2023[10]. - Net loss for the fiscal year ended June 30, 2024, was $2,571,440, a reduction from a net loss of $3,282,179 for the same period in 2023, reflecting a 22% improvement[20]. - Total operating expenses decreased to $2,620,858 for the fiscal year ended June 30, 2024, down from $3,408,160 in 2023, marking a 23% reduction[20]. - Basic and diluted net loss per share improved to $(0.34) for the fiscal year ended June 30, 2024, compared to $(1.35) in 2023, showing a significant improvement[20]. - Professional fees decreased to $614,082 for the fiscal year ended June 30, 2024, down from $976,638 in 2023, a reduction of 37%[20]. - General and administrative expenses decreased to $751,974 for the fiscal year ended June 30, 2024, down from $1,308,283 in 2023, indicating a 43% decrease[20]. Assets and Liabilities - Total current assets increased to $9,550,437 as of June 30, 2024, up from $6,225,788 on March 31, 2024, representing a 53% increase[18]. - Total liabilities rose to $2,702,801 as of June 30, 2024, compared to $2,479,650 on March 31, 2024, indicating an increase of approximately 9%[18]. - Cash and cash equivalents increased to $9,072,379 as of June 30, 2024, up from $5,441,978 on March 31, 2024, representing a 67% increase[18]. - Total stockholders' equity rose to $8,712,616 as of June 30, 2024, compared to $5,766,332 on March 31, 2024, reflecting a 51% increase[18]. - The weighted average number of common shares outstanding increased to 7,457,888 for the fiscal year ended June 30, 2024, compared to 2,431,476 in 2023, indicating a significant increase in shares[20]. Clinical Trials and Research - Aethlon Medical received two ethics committee approvals for a clinical trial of the Hemopurifier® in patients with solid tumors, with patient enrollment expected to open in October 2024[1][6]. - The primary endpoint of the upcoming trial is safety, monitoring adverse events and lab test changes in treated patients[6]. - The Hemopurifier has shown potential to improve therapeutic response rates to anti-PD-1 antibodies by binding and removing extracellular vesicles from the bloodstream[5]. - Aethlon Medical is exploring the Hemopurifier's use for treating life-threatening viral infections, with ongoing trials for COVID-19 in India[7]. - The company anticipates submitting applications to additional ethics committees in Australia and India, with potential approvals expected in late 2024[6]. - Aethlon Medical aims to conduct site initiation visits and begin patient enrollment at additional sites by the end of 2024[6].

Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies; Expects to Open Patient Enrollment in October of 2024 Achieved Significant 24% Reduction in Fiscal First Quarter Operating Expenses Compared to the Same Period in 2023Conference Call to be Held Today at 4:30 p.m. ETSAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeuti ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent news and developments for the treatment of solid cancer tumors, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.Read the full article at Investorideas.comhttps://www.investorideas.com/News/2024 ...

Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 AntibodiesSAN DIEGO, Aug. 12, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that, on August 6, 2024, the Bellberry Human Resea ...

SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal first quarter ended June 30, 2024, at 4:15 p.m. ET on Wednesday, August 14, 2024.Management will host a conference call on Wednesday, August 14, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following managem ...

Aethlon Medical, Inc. (NASDAQ:AEMD) Q4 2024 Earnings Conference Call June 27, 2024 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR James Frakes - Interim CEO and CFO Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Operator Good day and welcome to the Aethlon Medical Fiscal Year End of 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today’s presentation there will be an opportunity to as ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (MARK ONE) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR For the transition period from ________ to __________ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-36328 ...

Exhibit 99.1 Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company Updates Aethlon Medic ...

Conference Call to be Held Today at 4:30 p.m. ETSAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments. Company UpdatesAethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtration system de ...